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Phenotypic and genotypic characterization of
antimicrobial resistance in Escherichia coli
isolates
E. Igbinosa ∗, I. Ogboghodo, I.S. Obuekwe, F.E.
Oviasogie
University of Benin, Benin City, Nigeria
Background:Themajor inﬂuenceson the increase and spreadof
antimicrobial resistant bacteria are the use of antimicrobial agents
in human medicine and their use in livestock for therapy and
growth promotion. To generate baseline data to use in future risk
assessment of antimicrobial resistance, a number of surveillance
program on the local, continental and global scale have been ini-
tiated. The prevalence of resistance in commensal E. coli is a good
indicator for the selective pressure by antibiotics use and resis-
tance problems to be expected in pathogenic bacteria. The aim of
this studywas to determine and compare the occurrence of antimi-
crobial resistance phenotypes and genotypes among E. coli strains
recovered from animal sources.
Methods & Materials: Fifty-eight (58) E. coli strains were iso-
lated from animal sources (Cattle, pig and chicken). MIC was
determined according to Clinical and Laboratory Standards Insti-
tute (CLSI) guidelines. Strains were screened and mapped by PCR
methods for antimicrobial resistant genes, integrons and gene cas-
settes.
Results: The resistance proﬁle of E. coli for ampicillin
(100%), cefotaxime (100%), ceftazidime (83%), ciproﬂoxacin (43%)
(C), tetracycline (100%) (T), gentamicin (90%) (G), kanamycin
(77%) (K), streptomycin (100%) (S), chloramphenicol (97%) (Ch)
sulphamethoxazole (100%) (Su) and trimethoprime (97%) (T).
Eight-Five per cent (85%) of E. coli harbored class 1 integron and
variable gene cassettes were revealed. A prevalence of gene cas-
settes that present resistance to streptomycin and trimethoprime
was observed. The resistance genes determinant present in gen-
tamicin resistance were aac(3’)-IIc, aac(6’)-Ib and ant(2”)-1a. The
occurrence of aph(3)-Ia in kanamycin resistant strainswas 68%. The
prevalence of sul1 (80%) and sul2 (100%) was observed. The preva-
lence of tet(A) is higher than tet(B) in tetracycline-resistant strains.
The gene determinants for chloramphenicol resistance (cat1 and
catB) were detected. Differences in the rates and proﬁle of resis-
tance were observed, possibly reﬂecting differences in antibiotic
use regimens among these strains.
Conclusion: This study shows that multi-drug resistant E. coli
isolates are prevalent in animal sources and a considerable pro-
portion of E. coli strains are resistant to a variety of antimicrobial
agents.Genotypic characterization revealedhighnumberofdiverse
resistance determinants.
http://dx.doi.org/10.1016/j.ijid.2014.03.836
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New continuous ﬂuorometric assay for
bacterial transglycosylase
R. Cheng ∗
Academia Sinica, Taipei, Taiwan, R.O.C
Background: The emergence of antibiotic resistance has
prompted scientists to search for new antibiotics. Transglycosy-
lase (TGase) is an attractive target for new antibiotic discovery due
to its location on the outer membrane of bacteria and its essential
role in peptidoglycan synthesis. Though there are few molecules
identiﬁed as TGase inhibitors in the past thirty years, none of them
was developed into an antibiotics for humans. The slow pace of the
development is perhaps due to the lack of continuous, quantitative
and high-throughput assay available for the enzyme.
Methods & Materials: A new continuous ﬂuorescent assay
based on Förster resonance energy transfer, using lipid II ana-
logues with a dimethylamino-azobenzenesulfonyl quencher in the
lipid chain and a coumarin ﬂuorophore in the peptide chain was
developed. During the process of transglycosylation, the quencher-
appended polyprenol is released and the ﬂuorescence of coumarin
can be detected.
Results: Using this system, the substrate speciﬁcity and afﬁnity
of lipid II analogues bearing various numbers and conﬁgura-
tions of isoprene units were investigated. Moreover, the inhibition
constants of moenomycin and two previously identiﬁed small
molecules were also determined. In addition, a high-throughput
screening using the new assay was conducted to identify potent
TGase inhibitors from a 120,000 compound library.
Conclusion: This new continuous ﬂuorescent assay not only
provides an efﬁcient and convenient way to study TGase activities
but also enables the high-throughput screening of potential TGase
inhibitors for antibiotic discovery.
http://dx.doi.org/10.1016/j.ijid.2014.03.837
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Comparative in vitro activities of TR-1710 and
moxiﬂoxacin against Mycobacterium kansasii
M. Cynamon ∗, M. Sklaney, C. Shoen
Veterans Affairs Medical Center, Syracuse, NY, USA
Background: The currently recommended regimen for treat-
mentofpulmonaryM.kansasii infection is isoniazid (INH), rifampin
(RIF), and ethambutol (EMB) for 12 – 18 months. RIF is the key
agent in this regimen and EMB likely decreases the development
of resistance to RIF. It is unclear if INH plays a signiﬁcant role due
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to its poor in vitro activity against M. kansasii. Improved thera-
peutic regimens for this pathogen would be useful. The purpose of
the present study was to evaluate the comparative in vitro activi-
ties of TR-1710, a new pyrimidoindole DNA gyraseB inhibitor, and
moxiﬂoxacin, a GyrA inhibitor, against twenty two isolates of M.
kansasii. It is unlikely that cross resistance will be a problem with
gyrase inhibitors targeting different enzyme subunits.
Methods&Materials:TR-1710andmoxiﬂoxacinwereobtained
from Cubist Pharmaceuticals (San Diego, CA) and Bayer Pharma-
ceuticals (West Haven, CT) respectively. These compounds were
dissolved in DMSO to a concentration of 1mg/ml prior to freez-
ing at -200C. They were tested in Middlebrook 7H9 broth, pH6.6
supplemented with 10% Middlebrook albumin-dextrose-catalase
enrichmentat2g/ml–0.002g/ml inpolystyrene96-well round-
bottom microtiter plates. To each well, 50l of mycobacterial cell
suspension was added to yield an initial concentration of about 1
x 105 CFU/ml (range for various isolates tested was 3.8 x103 – 1.2
x 106CFU/ml). Plates were incubated at 370C in ambient air for 7 -
10 days prior to reading.
Results:TR-1710andmoxiﬂoxacinhad similar activities against
M. kansasii in vitro. The MIC50/MIC90 (g/ml) of TR-1710 and
moxiﬂoxacin were 0.03/0.06 and 0.06/0.50 respectively.
Conclusion: Based on TR-1710’s promising in vitro activity, it
would be interesting to evaluate the comparative activities of TR-
1710 and moxiﬂoxacin in a murine model of M. kansasii infection,
as the next step in deﬁning the potential of gyrase inhibitors in the
treatment of these infections in humans.
http://dx.doi.org/10.1016/j.ijid.2014.03.838
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Do renin-angiotensin-aldosteron system
inhibitors protect kidneys during vancomycin
administration?
T. Kitazawa1,∗, K. Seo1, Y. Wakabayashi2, S.
Suzuki2, Y. Yoshino1, I. Koga1, Y. Ota1
1 Teikyo university, Tokyo, Japan
2 The University of Tokyo, Tokyo, Japan
Background:Vancomycin iswidely used for treatment ofMRSA
infection. For safe use of vancomycin, it is important to employ
the therapeutic drug monitoring, although renal function can get
worse even by maintaining the safe concentration of vancomycin.
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) are antihypertensives which are known
to block renin-angiotensin-aldosteron system and to have renal
protecting effect. However, there has been no study investigating
the effect of ACEIs or ARBs on renal protection during vancomycin
administration. In this studywe investigated the inﬂuence of ACEIs
or ARBs on renal function during the vancomycin administration.
Methods & Materials: All the hospitalized patients who receive
vancomycin intravenously in the department of internal medicine
in the Teikyo University hospital from September 2010 to February
2013 were enrolled. Patients who received other potential nephro-
toxic agents, those who stopped receiving vancomycin due to
other reason than renal dysfunction, or those who died during the
treatment were excluded. All the patients were divided into three
groups; ACEI/ARB groups, other antihypertensive group, and non-
antihypertensive group. Clinical backgrounds, trough vancomycin
concentrations, and changes of estimated glomerular ﬁltration
rates (eGFRs) were compared by reviewing medical records. Acute
kidney injury (AKI) was deﬁned as increase in the serum creatinine
concentration of ≥0.3mg/dL from baseline.
Results: Thirty one patients were enrolled in this study.
ACEI/ARB group were nine, other antihypertensive group were
nine, and non-antihypertensive groups were 13. Among clinical
backgrounds, only the ratio of hypertension was lower in the non-
hypertensive group than in the other two groups. Mean trough
vancomycin concentrations were not different between the three
groups (15.3 vs 16.0 vs 14.7g/mL, P=0.86).Mean eGFRs at the van-
comycin initiation and at the vancomycin termination were not
statistically different between the three groups (59.0 vs 57.4 vs
58.8mL/min/1.73m2, P=0.61; 60.5 vs 57.1 vs 57.2mL/min/1.73m2,
P=0.80, respectively). The ratio of AKI was not statistically different
between the three groups (3/9 vs 1/9 vs 1/13, P=0.24).
Conclusion:ACEIs or ARBs did not protect renal function during
vancomycin administration.
http://dx.doi.org/10.1016/j.ijid.2014.03.839
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Nitroxoline for treatment of uncomplicated
UTI: IPD meta-analysis of four controlled
clinical studies
K.G. Naber1,∗, H. Niggemann2, G. Stein3
1 Technical University of Munich, Munich, Germany
2 Statistical Consulting & Analysis, Jena, Germany
3 Rosen Pharma GmbH, Blieskastel, Germany
Background: Nitroxoline, a hydroxychinolin derivate, is used
for many years for treatment of urinary tract infections (UTI). Four
controlled clinical studies concerning treatment of uncomplicated
UTI (uUTI) not published yet were meta-analysed.
Methods & Materials: The individual patient data (IPD) of 466
females with acute sporadic or acute episodes of recurrent uUTI
of four prospective, controlled, single blind, randomized clinical
studieswith similar protocols using nitroxoline (250mg tid) versus
cotrimoxazole (960mg bid) or norﬂoxacin (400mg bid) as controls
for ﬁve (three studies) or ten (one study) days were meta-analysed
by the same criteria. The primary efﬁcacy was the eradication
of bacteriuria. Success was deﬁned if pretreatment bacteriuria of
≥105CFU/ml was reduced to < 104CFU/ml 7-13 days after end of
therapy (test of cure). Clinical efﬁcacy was determined by elimi-
nation of symptoms and safety by adverse events and laboratory
tests.
Results: A total of 234 patients were treated orally with nitrox-
oline and 232 with the controls. The safety of nitroxoline was very
good and comparable to the controls (total adverse events 9.4% vs
7.8%). In the modiﬁed microbiological ITT set (at least one outcome
result available), in the PP set (test of cure outcome available) and
in the modiﬁed PP set (missing test of cure rated failure) more than
90% of the patients showed eradication of bacteriuria with nitrox-
oline, which also met statistical non-inferiority compared to the
controls (10% non-inferiority margin) in all three evaluation sets.
